Dr. Kerstin Huemer

Establishment of Gilead Medical Affairs in Hematooncology and CAR-T-Cell Therapy as new major, sustainable therapeutic areas as basis for future growth. Medical Launch of Zydelig® & Yescarta® (a designated orphan medicine gene therapy product). Responsibility for pipeline compounds in hematooncology and solid tumours. • Country Medical Lead Hematooncology / CAR-T-Cell Therapy • Interims X-Functional Country Lead CAR-T-Cell Therapy • Medical Strategy & Tactics • Key Opinion Leader Management

Commercial launch preparation of Avastin® in glioblastoma. Product management of Avastin® in mamma carcinoma. • Marketing Strategy and Tactics • Budget & Revenue Responsibility • Key Opinion Leader Management • Sales Force Training • Market Monitoring

Medical launch of Perjeta® and Kadcyla® including implementation of Named Patient Use. Medical management of Herceptin®. • Medical Strategy & Tactics • Planning, budgeting and conduct of phase II- and III-trials incl. technical responsibility for clinical monitors • Key Opinion Leader Management • Advisory Boards • Medical Education • Medical Information • Investigator Sponsored Trials • Medical Support of Commercial Strategy • Internal Medical Training • Budget Responsibility

Implementation of STRATIFY JCV™ Assay to ensure safety of patients treated with Tysabri®. • Key Opinion Leader Management • Medical Education

First MSL at Novartis Pharma in Austria to prove the value of the business model of field based medical staff in the pharmaceutical industry in Europe. • Investigator Sponsored Trials • Key Opinion Leader Management • Medical Education • Medical Support of Marketing and Sales • Public Relations Projects